AG Mednet Addresses Cardiovascular Trial Needs for Data Collection and Quality
AG Mednet announced the availability of new capabilities to enable sponsors, CROs and core laboratories to take delivery of electronic trial data
AG Mednet announced the availability of new capabilities to enable sponsors, CROs and core laboratories to take delivery of electronic trial data into configurable file structures residing either locally or in any of their network shares. By allowing meta-data to be assigned to non-DICOM modalities , this provides for better quality data and less delays for modalities that do not yet conform to the DICOM standard. These include Holter data, spectral domain OCT and others.
For sites participating in AG Mednet-based trials, the imaging submissions remain consistent across the DICOM and non-DICOM data sets. For sponsors, CROs and core labs, non-DICOM modalities are delivered to a file system-based infrastructure, while DICOM modalities are delivered either to a standard DICOM environment, or the same file system-based infrastructure.
You can read the full release here.
Semaglutide Significantly Improves Steatohepatitis, Fibrosis in Phase III MASH Trial
May 2nd 2025Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly semaglutide improved liver histology, metabolic markers, and weight loss in patients with biopsy-confirmed metabolic dysfunction–associated steatohepatitis and stage 2 or 3 fibrosis.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
